Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 14, 2003, Pages 3205-3214

  Dardonville, Christophe ^a   Rinaldi, Eliana ^b   Hanau, Stefania ^b   Barrett, Michael P ^c   Brun, Reto ^d   Gilbert, Ian H ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; LIVER ENZYME; OXIDOREDUCTASE INHIBITOR; PHOSPHOGLUCONATE DEHYDROGENASE;

AFRICAN TRYPANOSOMIASIS; ARTICLE; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ANALYSIS; IN VITRO STUDY; LEISHMANIA DONOVANI; LIVER; NONHUMAN; SHEEP; TRYPANOSOMA CRUZI; TRYPANOSOMA RHODESIENSE;

LEISHMANIA DONOVANI; OVIS ARIES; TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMA CRUZI;

EID: 0037785388     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00191-3     Document Type: Article

References (36)

1. WHO/CDS/CSR/ISR/2000.1, http://www.who.int/emc.
2. http://www.who.int/tdr/diseases/tryp/diseaseinfo.htm.
3. World Health Organ. Tech. Rep. Ser. 1998, 881, 1.
4. (a) De Koning H.P. Int. J. Parasitol. 31:2001;512
5. (b) Denise H., Barrett M.P. Biochem. Pharmacol. 61:2001;1.
6. Keiser J., Stich A., Burri C. TRENDS Parasitol. 17:2001;42.
7. (a) Opperdoes F.R. Biochem. Soc. Trans. 18:1990;729
8. (b) Opperdoes F.R., Michels P.A.M. Int. J. Parasitol. 31:2001;482.
9. Barrett M.P. Parasitol. Today. 13:1997;11.
10. Barrett M.P., Le Page R.W.F. Mol. Biochem. Parasitol. 57:1993;89.
11. Barrett M.P., Phillips C., Adams M.J., LePage R.W.F. Protein Expres. Purif. 5:1994;44.
12. Krepinsky K., Plaumann M., Martin W., Schnarrenberger C. Eur. J. Biochem. 268:2001;2678.
13. Phillips C., Dohnalek J., Gover S., Barrett M.P., Adams M.J. J. Mol. Biol. 282:1998;667.
14. Barrett M.P., Gilbert I.H. Curr. Topics Med. Chem. 2:2002;471.
15. Marchand M., Kooystra U., Wierenga R.K., Lambeir A.-M., Beeumen J.V., Opperdoes F.R., Michels P.A. Eur. J. Biochem. 184:1989;455.
16. Lobo Z., Maitra P.K. Mol. Gen. Genet. 185:1982;367.
17. Gvozdev V.A., Gerasimova T.I., Kogan G.L., Braslavskaya O.Yu. FEBS Lett. 64:1976;85.
18. (a) Phillips C., Gover S., Adams M.J. Acta Cryst. D51:1995;290
19. (b) Adams M.J., Ellis G.H., Gover S., Naylor C.E., Phillips C. Structure. 2:1994;651.
20. Pasti, C.; Rinaldi, E.; Cervellati, C.; Dallocchio, F.; Hardré, R.; Salmon, L.; Hanau, S. Bioorg. Med. Chem. 2003, 11, 1207.
21. (a) Hanau S., Rippa M., Bertelli M., Dallocchio F., Barrett M.P. Eur. J. Biochem. 240:1996;592
22. (b) Rippa M., Giovannini P.P., Barrett M.P., Dallocchio F., Hanau S. Biochim. Biophys. Acta. 1429:1998;83.
23. Bertelli M., El-Bastawissy E., Knaggs M.H., Barrett M.P., Hanau S., Gilbert I.H. J. Comput. Aid. Mol. Des. 15:2001;465.
24. Berdis A.J., Cook P.F. Biochemistry. 32:1993;2041.
25. Details of the development of our synthetic approach for the preparation of the (2R)-2-methyl-4-deoxy analogues (compounds 2, 3, 6, 8, 10, 12, 14-18, 20, 21) and (2R)-2-methyl-4,5-dideoxy analogues (compounds 26-32) have been described elsewhere: Dardonville C., Gilbert I.H. Org. Biomol. Chem. 1:2003;552.
26. Evans D.A. Aldrichim. Acta. 15:1982;23.
27. (a) Meyers A.I., Lawson J.P., Walker D.G., Linderman R.J. J. Org. Chem. 51:1986;5111
28. (b) Hanessian S., Ugolini A., Therien M. J. Org. Chem. 48:1983;4427
29. (c) Boger D.L., Curran T.T. J. Org. Chem. 57:1992;2235.
30. (a) Ueno Y., Miyamo T., Okawara M. Tetrahedron Lett. 23:1982;443
31. (b) Vedejs E., Powell D.W. J. Am. Chem. Soc. 104:1982;2046.
32. Evans D.A., Britton T.C., Ellman J.A. Tetrahedron Lett. 28:1987;6141.
33. (a) Gefflaut T., Lemaire M. Valentin, M-L., Bolte, J. J. Org. Chem. 62:1997;5920
34. (b) Kis K., Wungsintaweekul J., Eisenreich W., Zenk M.H., Bacher A. J. Org. Chem. 65:2000;587.
35. It should be noted that compounds 20 and 22 could not be obtained in a pure form directly by hydrogenolysis of 12 and 13, respectively. Phosphate migration ability of this kind of molecules has been discussed in another article. See ref 21.
36. We used 5% Pd/C from Fluka Chemical company to avoid early deprotection of the THP. Kaisalo L.H., Hase T.A. Tetrahedron Lett. 42:2001;7699.